Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
How is pediatric and young adult primary bone lymphoma risk stratified?
I can only talk to the pediatric experience. Studies done a number of years ago showed that multiple bone lymphoma does not give a poorer prognosis and therefore in Pediatric NHL, even widespread bone is not stage IV or FAB LMB Group C. If B-lineage, it would be stage III or Group B hence 4 courses ...
When giving single agent docetaxel for patients with metastatic NSCLC who have progressed on platinum and immunotherapy, do you stop after 6 cycles or do you continue as long as tolerated and disease is stable?
When giving docetaxel to patients with NSCLC who have disease progression after platinum chemotherapy and immunotherapy, I typically give it in combination with ramucirumab per the REVEL study (Garon et al., PMID 24933332). In this study, patients with NSCLC who had disease progression after platinu...
How do you approach evaluation of pulmonary vein thrombosis?
Pulmonary vein thrombosis is a rare condition that is usually associated with injury to the vessel, for example after surgery or lung transplantation, or as a complication of lung cancer. I am not aware of any data on the relative efficacy of different anticoagulants in PVT but from a biologic persp...
Would you consider bone marrow transplant in a pediatric patient with recurrent HLH with no identified exogenous trigger or HLH-associated mutation?
What is your approach for adjuvant endocrine therapy in a female with HR+ breast cancer with history of provoked DVT while on OCPs?
In a postmenopausal female with HR+HER2- breast cancer and a history of DVT on OCPs, I would recommend adjuvant endocrine therapy with an aromatase inhibitor and not tamoxifen. This is based on improved efficacy for aromatase inhibitors compared to tamoxifen in this population, and VTE risk associat...
What factors besides disease progression would lead you to de-intensify or change MM therapy for a patient with ongoing response?
After initial therapy (which may or may not include an autologous stem cell transplant), patients are generally on continuous/maintenance therapy with e.g. lenalidomide as the most common regimen. Most patients do well on this as maintenance. However, loose stools are probably the most common compla...
How do you counsel patients with newly diagnosed transplant-ineligible multiple myeloma on the expectations of treatment in terms of disease control, duration of therapy, monitoring and follow up?
I'm going to take this question very literally and write a paraphrase of my general explanation to patients at an initial diagnosis and treatment planning visit. Forgive me, this is long, a paraphrase of a 30-60 minute visit with a patient. I hope this will result in others sharing how they navigate...
When do you consider re-treatment with lenalidomide in later line therapy for relapsed multiple myeloma?
It is a challenging question due to the fact all studies post lenalidomide failure even in maintenance never included lenalidomide based therapy in first up to third line of therapy: such as Dara/Pom/dex, Dara/Car/dec, Elo/Pom/dex, Pom/Vel/dex … some argue that since the patient was on low dose of l...
What is your preferred adjuvant treatment option for a patient with stage III BRAF-mutated melanoma and a history of a solid organ transplantation on immunosuppressants?
What is the preferred number of cycles of CAPOX for rectal cancer receiving total neoadjuvant chemotherapy?
The treatment of rectal cancer is probably more confusing than ever before!The typical approach to “TNT” has been to give 4 months (8 cycles) of FOLFOX.The optimal duration of Capox is less defined.One reasonable option would be to aim for the same duration of 4 months. This would be ~5-6 cycles of ...